Morningstar ID: 0P0001HE2G
Exchange: NASDAQ-GM
Sector: Healthcare
Industry: Biotechnology
Stock Style: Small Value
description: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
(Generated: 2025-06-23 23:56:32)
| Income Statement As of Originally Reported | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 9990000 | 460000 | 270000 | ||
| Revenue Growth % | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | -95.45 | 40.00 |
| Gross Profit | |||||||||||
| Gross Profit Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -4290000 | -13520000 | -45580000 | -94470000 | -105620000 | -82950000 | -64540000 | -104300000 | -108730000 | ||
| Operating Margin % | - | - | - | - | - | - | - | - | -645.80 | -22922.86 | -40875.94 |
| EBIT | -4290000 | -14880000 | -45610000 | -94520000 | -106140000 | -83190000 | -121140000 | -109160000 | -47080000 | ||
| EBIT Margin % | - | - | - | - | - | - | - | - | -1212.20 | -23990.77 | -17698.87 |
| EBITDA | -4290000 | -14880000 | -45580000 | -94140000 | -105720000 | -82750000 | -120780000 | -108730000 | -46670000 | ||
| EBITDA Margin % | - | - | - | - | - | - | - | - | -1208.66 | -23897.14 | -17544.74 |
| Net Income | -4280000 | -16520000 | -45510000 | -93960000 | -105580000 | -82510000 | -119760000 | -105620000 | -43510000 | ||
| Net Profit Margin % | - | - | - | - | - | - | - | - | -1198.47 | -23214.07 | -16357.52 |
| Basic EPS | - | - | -0.47 | -1.80 | -3.55 | -4.28 | -4.12 | -2.18 | -1.42 | -0.76 | -0.28 |
| Diluted EPS | - | - | -0.47 | -1.80 | -3.55 | -4.28 | -4.12 | -2.18 | -1.42 | -0.76 | -0.43 |
| Normalized EPS | - | - | - | -1.68 | -2.48 | -4.28 | -4.12 | -2.48 | -0.90 | -0.81 | -0.75 |
| Dividend Per Share | - | - | - | - | - | - | - | - | - | - | - |
| Balance Sheet As of Originally Reported | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Last Quarter |
| Total Assets | 3290000 | 20250000 | 48390000 | 104510000 | 89890000 | 38360000 | 54830000 | 86690000 | 56910000 | ||
| Total Liabilities | 7250000 | 4430000 | 15780000 | 22570000 | 27350000 | 34300000 | 71980000 | 29690000 | 20240000 | ||
| Total Debt | 0 | 0 | 2040000 | 2810000 | 2120000 | 1510000 | 780000 | 2800000 | 2700000 | ||
| Total Equity | -3960000 | 15820000 | 32610000 | 81940000 | 62540000 | 4060000 | -17150000 | 57010000 | 36670000 | ||
| Cash And Cash Equivalents | 3280000 | 18750000 | 18850000 | 57470000 | 53890000 | 16660000 | 49900000 | 79400000 | 50760000 | ||
| Working Capital | 2290000 | 15820000 | 32060000 | 81360000 | 61930000 | 3880000 | -16800000 | 56350000 | 36000000 | ||
| Shares Outstanding Capital | 17130000 | 22490000 | 26220000 | 48060000 | 77230000 | 116360000 | 116360000 | ||||
| Book Value per Share | - | - | - | - | 1.76 | 3.64 | 2.39 | 0.08 | -0.20 | 0.42 | 0.26 |
| Debt to Equity | - | - | - | 0.00 | 0.06 | 0.03 | 0.03 | 0.37 | - | 0.05 | 0.07 |
| Cash Flow As of Originally Reported | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
| Cash From Operating Activities | -3200000 | -11180000 | -36310000 | -78210000 | -90730000 | -78090000 | -55170000 | -84310000 | -94030000 | ||
| Cash From Investing Activities | -20010000 | -19470000 | 12430000 | 13170000 | 13870000 | 0 | 0 | ||||
| Cash From Financing Activities | 6470000 | 26650000 | 56420000 | 136290000 | 74720000 | 27690000 | 74540000 | 113810000 | -1690000 | ||
| Capital Expenditure | |||||||||||
| Free Cash Flow | -3760000 | -13250000 | -39540000 | -83360000 | -94400000 | -69250000 | -53730000 | -86830000 | -92480000 | ||
| Change in Cash | 3280000 | 15470000 | 100000 | 38620000 | -3580000 | -37230000 | 33240000 | 29500000 | -95720000 |
| Unnamed: 0 | 2015-12 | 2016-12 | 2017-12 | 2018-12 | 2019-12 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | 2024-12 | Latest Qtr |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue % | |||||||||||
| Year Over Year | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | -95.45 | 0.00 |
| 3-Year Average | - | - | - | - | - | 0.00 | 0.00 | 0.00 | - | - | - |
| 5-Year Average | - | - | - | - | - | - | - | 0.00 | - | - | - |
| 10-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income % | |||||||||||
| Year Over Year | - | - | - | - | - | - | - | - | - | - | - |
| 3-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 5-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 10-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| Net Income % | |||||||||||
| Year Over Year | - | - | - | - | - | - | - | - | - | - | - |
| 3-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 5-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 10-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| EPS % | |||||||||||
| Year Over Year | - | - | - | - | - | - | - | - | - | - | - |
| 3-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 5-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| 10-Year Average | - | - | - | - | - | - | - | - | - | - | - |
| Cash Flow Ratios | Unnamed: 1 | Unnamed: 2 | 2017-12 | 2018-12 | 2019-12 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | 2024-12 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow Growth % YOY | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow Growth % YOY | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow/Sales % | - | - | - | - | - | - | - | - | -552.12 | -18528.57 | -35483.02 |
| Free Cash Flow/Net Income | - | - | 0.75 | 0.68 | 0.80 | 0.83 | 0.86 | 0.95 | 0.46 | 0.80 | 2.16 |
| Free Cash Flow/Share | - | - | - | - | -1.74 | -3.65 | -3.50 | -2.80 | -0.78 | -0.62 | -0.62 |
| Liquidity/Financial Health | 2015-12 | 2016-12 | 2017-12 | 2018-12 | 2019-12 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | 2024-12 | Latest Qtr |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | - | - | 3.31 | 4.57 | 3.27 | 4.83 | 3.34 | 1.12 | 0.76 | 3.06 | 3.00 |
| Quick Ratio | - | - | 3.30 | 4.23 | 2.76 | 4.58 | 3.07 | 0.92 | 0.71 | 2.91 | 2.83 |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - | - |
| Financial Leverage | - | - | - | 1.28 | 1.48 | 1.28 | 1.44 | 9.45 | - | 1.52 | 1.55 |
| Debt/Equity | - | - | - | - | 0.05 | 0.02 | 0.01 | 0.10 | - | 0.04 | 0.06 |
| Book Value/Share | - | - | - | - | 1.66 | 4.58 | 3.31 | 0.20 | -0.13 | 0.04 | 0.04 |
| Cap Ex as a % of Sales | - | - | - | - | - | - | - | - | - | - | - |
| Fiscal | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Current | 5-Yr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Asset % | - | - | -130.31 | -140.41 | -132.62 | -122.91 | -108.63 | -128.66 | -257.01 | -149.27 | -41.81 | -126.98 |
| Return on Equity % | - | - | - | -278.67 | -187.97 | -164.06 | -146.16 | -247.77 | - | -529.97 | -83.71 | -155.37 |
| Return on Invested Capital % | - | - | - | -278.67 | -173.37 | -157.39 | -141.33 | -234.95 | - | -502.66 | -88.00 | -150.15 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | 0.0 |
| Days Inventory | - | - | - | - | - | - | - | - | - | - | - | 0.0 |
| Payables Period | - | - | - | - | - | - | - | - | - | - | - | 0.0 |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | 0.0 |
| Recieveables Turnover | - | - | - | - | - | - | - | - | - | - | - | 0.0 |
| Inventory Turnover | - | - | - | - | - | - | - | - | - | - | - | 0.0 |
| Fixed Assets Turnover | - | - | - | - | - | - | - | - | 13.31 | 0.28 | 0.18 | 0.0 |
| Asset Turnover | - | - | - | - | - | - | - | - | 0.21 | 0.01 | 0.00 | 0.0 |
